Dengue fever typically presents with a sudden high fever, often reaching up to 104°F (40°C). Patients may experience severe headaches, pain behind the eyes, and intense joint and muscle pain, which is why dengue is sometimes referred to as "breakbone fever." A rash may appear a few days after the fever begins, and mild bleeding, such as nosebleeds or gum bleeding, can occur. In severe cases, the disease can progress to dengue hemorrhagic fever, characterized by bleeding, blood plasma leakage, and low platelet count, or dengue shock syndrome, which can be life-threatening.

Diagnosing dengue fever involves a combination of clinical evaluation and laboratory tests. A healthcare provider will assess the patient's symptoms and travel history to areas where dengue is common. Laboratory tests can confirm the diagnosis by detecting the virus or antibodies in the blood. These tests include the NS1 antigen test, which detects the virus early in the infection, and serological tests that identify antibodies produced in response to the virus. A complete blood count (CBC) may also be performed to check for low platelet levels and other blood abnormalities.

There is no specific antiviral treatment for dengue fever. Management focuses on relieving symptoms and preventing complications. Patients are advised to rest, stay hydrated, and take pain relievers such as acetaminophen to reduce fever and alleviate pain. Aspirin and non-steroidal anti-inflammatory drugs (NSAIDs) should be avoided due to the risk of bleeding. In severe cases, hospitalization may be necessary to provide supportive care, such as intravenous fluids and blood transfusions, to manage complications like dehydration and bleeding.

The prognosis for dengue fever is generally good, with most patients recovering fully within two weeks. However, the disease can be severe and even fatal, particularly in cases of dengue hemorrhagic fever or dengue shock syndrome. Early diagnosis and appropriate medical care are crucial in reducing the risk of complications and improving outcomes. With proper management, the mortality rate for severe dengue can be reduced to less than 1%.

Dengue fever is caused by the dengue virus, which belongs to the Flavivirus genus. There are four distinct serotypes of the virus (DENV-1, DENV-2, DENV-3, and DENV-4), and infection with one serotype provides lifelong immunity to that serotype but not to the others. Subsequent infections with different serotypes increase the risk of severe dengue. The virus is primarily transmitted to humans through the bite of infected Aedes mosquitoes, particularly Aedes aegypti.

Dengue fever is endemic in over 100 countries, with the highest burden in Southeast Asia, the Western Pacific, the Americas, and Africa. The World Health Organization estimates that there are 100-400 million dengue infections each year, with about 500,000 cases of severe dengue requiring hospitalization. Urbanization, increased travel, and climate change have contributed to the spread of the disease. Outbreaks are more common during the rainy season when mosquito populations are higher.

The pathophysiology of dengue involves the virus entering the body through a mosquito bite and infecting cells of the immune system. The immune response to the virus causes the release of inflammatory mediators, leading to the symptoms of fever, pain, and rash. In severe cases, the immune response can cause increased vascular permeability, leading to plasma leakage, bleeding, and shock. The risk of severe disease is higher in individuals with a second infection by a different serotype, due to a phenomenon known as antibody-dependent enhancement.

Preventing dengue fever primarily involves controlling mosquito populations and avoiding mosquito bites. This can be achieved by eliminating standing water where mosquitoes breed, using insect repellent, wearing long-sleeved clothing, and using mosquito nets. Community-based efforts to reduce mosquito habitats and the use of insecticides can also help control the spread of the disease. A dengue vaccine, Dengvaxia, is available in some countries for individuals who have had a previous dengue infection, but it is not recommended for those who have never been infected.

Dengue fever is a mosquito-borne viral disease prevalent in tropical and subtropical regions. It presents with flu-like symptoms and can progress to severe forms with potentially life-threatening complications. Diagnosis is confirmed through clinical evaluation and laboratory tests. While there is no specific treatment, supportive care can effectively manage symptoms and prevent complications. Prevention focuses on mosquito control and personal protective measures. Understanding the disease's epidemiology, pathophysiology, and prevention strategies is crucial in reducing its impact.

If you suspect you have dengue fever, it is important to seek medical attention, especially if you have recently traveled to an area where the disease is common. Symptoms include high fever, severe headache, joint and muscle pain, and rash. While there is no specific cure, rest, hydration, and pain relief can help manage symptoms. Avoid taking aspirin or NSAIDs, as they can increase the risk of bleeding. Preventing mosquito bites and reducing mosquito habitats are key to avoiding infection. If you have had dengue before, be aware of the increased risk of severe disease with subsequent infections.